Protegrin

Last updated
Identifiers
SymbolN/A
OPM superfamily 203
OPM protein 1pg1

Protegrins are small peptides containing 16-18 amino acid residues. Protegrins were first discovered in porcine leukocytes and were found to have antimicrobial activity against bacteria, fungi, and some enveloped viruses. [1] The amino acid composition of protegrins contains six positively charged arginine residues and four cysteine residues. [2] Their secondary structure is classified as cysteine-rich β-sheet antimicrobial peptides, AMPs, that display limited sequence similarity to certain defensins and tachyplesins. In solution, the peptides fold to form an anti-parallel β-strand with the structure stabilized by two cysteine bridges formed among the four cysteine residues. [3] Recent studies suggest that protegrins can bind to lipopolysaccharide, a property that may help them to insert into the membranes of gram-negative bacteria and permeabilize them. [4]

Contents

Structure

There are five known porcine protegrins, PG-1 to PG-5. [5] Three were identified biochemically and rest of them were deduced from DNA sequences. [6]

Protegrin structures Protegrin structures.png
Protegrin structures

The protegrins are synthesized from quadiripartite genes as 147 to 149 amino acid precursors with a cathelin-like propiece. [5] [7] Protegrin sequence is similar to certain prodefensins and tachyplesins, antibiotic peptides derived from the horseshoe crab. [1] Protegrin-1 that consists of 18 amino acids, six of which are arginine residues, forms two antiparallel β-sheets with a β-turn. Protegrin-2 is missing two carboxy terminal amino acids. So, Protegrin-2 is shorter than Protegrin-1 and it has one less positive charge. Protegrin-3 substitutes a glycine for an arginine at position 4 and it also has one less positive charge. Protegrin-4 substitutes a phenylalanine for a valine at position 14 and sequences are different in the β-turn. This difference makes protegrin-4 less polar than others and less positively charged. Protegrin-5 substitutes a proline for an arginine with one less positive charge. [5]

Mechanism of action

Protegrin-1 induces membrane disruption by forming a pore/channel that leads to cell death. [8] [9] This ability depends on its secondary structure. [10] It forms an oligomeric structure in the membrane that creates a pore. Two ways of the self association of protegrin-1 into a dimeric β-sheet, an antiparallel β-sheet with a turn-next-to-tail association or a parallel β-sheet with a turn-next-to-turn association, [11] were suggested. The activity can be restored by stabilizing the peptide structure with the two disulfide bonds. [12] The interacts with membranes depends on membrane lipid composition [13] and the cationic nature of the protegrin-1 adapts to the amphipathic characteristic which is related to the membrane interaction. [9] The insertion of Protegrin-1 into the lipid layer results in the disordering of lipid packing to the membrane disruption. [13]

Antimicrobial activity

The protegrins are highly microbicidal against Candida albicans, [14] Escherichia coli, [15] Listeria monocytogenes, Neisseria gonorrhoeae, [16] and the virions of the human immunodeficiency virus in vitro under conditions which mimic the tonicity of the extracellular milieu. [1] [5] [17] The mechanism of this microbicidal activity is believed to involve membrane disruption, similar to many other antibiotic peptides [5] [18]

Mimetics as antibiotics

Protegrin-1 (PG-1) peptidomimetics developed by Polyphor AG and the University of Zurich are based on the use of the beta hairpin-stabilizing D-Pro-L-Pro template which promote a beta hairpin loop structure found in PG-I. Fully synthetic cyclic peptide libraries of this peptidomimetic template produced compounds that had an antimicrobial activity like that of PG-1 but with reduced hemolytic activity on human red blood cells. [19] Iterative rounds of synthesis and optimization led to the pseudomonas -specific clinical candidate Murepavadin that successfully completed phase-II clinical tests in hospital patients with life-threatening Pseudomonas lung infections. [20]

Related Research Articles

<span class="mw-page-title-main">Peripheral membrane protein</span> Membrane proteins that adhere temporarily to membranes with which they are associated

Peripheral membrane proteins, or extrinsic membrane proteins, are membrane proteins that adhere only temporarily to the biological membrane with which they are associated. These proteins attach to integral membrane proteins, or penetrate the peripheral regions of the lipid bilayer. The regulatory protein subunits of many ion channels and transmembrane receptors, for example, may be defined as peripheral membrane proteins. In contrast to integral membrane proteins, peripheral membrane proteins tend to collect in the water-soluble component, or fraction, of all the proteins extracted during a protein purification procedure. Proteins with GPI anchors are an exception to this rule and can have purification properties similar to those of integral membrane proteins.

<span class="mw-page-title-main">Polymyxin</span> Group of antibiotics

Polymyxins are antibiotics. Polymyxins B and E are used in the treatment of Gram-negative bacterial infections. They work mostly by breaking up the bacterial cell membrane. They are part of a broader class of molecules called nonribosomal peptides.

<span class="mw-page-title-main">Beta-peptide</span> Class of peptides derived from β-amino acids

Beta-peptides (β-peptides) are peptides derived from β-amino acids, in which the amino group is attached to the β-carbon (i.e. the carbon two atoms away from the carboxylate group). The parent β-amino acid is β-alanine (H2NCH2CH2CO2H), a common natural substance, but most examples feature substituents in place of one or more C-H bonds. β-peptides usually do not occur in nature. β-peptide-based antibiotics are being explored as ways of evading antibiotic resistance. Early studies in this field were published in 1996 by the group of Dieter Seebach and that of Samuel Gellman.

<span class="mw-page-title-main">Defensin</span> Group of antimicrobial peptides

Defensins are small cysteine-rich cationic proteins across cellular life, including vertebrate and invertebrate animals, plants, and fungi. They are host defense peptides, with members displaying either direct antimicrobial activity, immune signaling activities, or both. They are variously active against bacteria, fungi and many enveloped and nonenveloped viruses. They are typically 18-45 amino acids in length, with three or four highly conserved disulphide bonds.

<span class="mw-page-title-main">Antimicrobial peptides</span> Class of peptides that have antimicrobial activity

Antimicrobial peptides (AMPs), also called host defence peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antimicrobials which demonstrate potential as novel therapeutic agents. Antimicrobial peptides have been demonstrated to kill Gram negative and Gram positive bacteria, enveloped viruses, fungi and even transformed or cancerous cells. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as immunomodulators.

<span class="mw-page-title-main">Surfactin</span> Chemical compound

Surfactin is a cyclic lipopeptide, commonly used as an antibiotic for its capacity as a surfactant. It is an amphiphile capable of withstanding hydrophilic and hydrophobic environments. The Gram-positive bacterial species Bacillus subtilis produces surfactin for its antibiotic effects against competitors. Surfactin showcases antibacterial, antiviral, antifungal, and hemolytic effects.

<span class="mw-page-title-main">Cathelicidin</span> Group of antimicrobial peptides in vertebrates

Cathelicidin antimicrobial peptide (CAMP) is a polypeptide that is primarily stored in the lysosomes of macrophages and polymorphonuclear leukocytes (PMNs); in humans, the CAMP gene encodes the peptide precursor CAP-18, which is processed by proteinase 3-mediated extracellular cleavage into the active form LL-37. LL-37 is the only peptide in the Cathelicidin family found in the human body.

<span class="mw-page-title-main">Alpha defensin</span>

Alpha defensins are a family of mammalian defensin peptides of the alpha subfamily. In mammals they are also known as cryptdins and are produced within the small bowel. Cryptdin is a portmanteau of crypt and defensin.

<span class="mw-page-title-main">Beta defensin</span>

Beta defensins are a family of vertebrate defensins. The beta defensins are antimicrobial peptides implicated in the resistance of epithelial surfaces to microbial colonization.

<span class="mw-page-title-main">DEFA1</span> Protein-coding gene in the species Homo sapiens

Defensin, alpha 1 also known as human alpha defensin 1, human neutrophil peptide 1 (HNP-1) or neutrophil defensin 1 is a human protein that is encoded by the DEFA1 gene. Human alpha defensin 1 belongs to the alpha defensin family of antimicrobial peptides.

<span class="mw-page-title-main">DEFA5</span> Mammalian protein found in Homo sapiens

Defensin, alpha 5 (DEFA5) also known as human alpha defensin 5 (HD5) is a protein that in humans is encoded by the DEFA5 gene. DEFA5 is expressed in the Paneth cells of the ileum.

<span class="mw-page-title-main">DEFA6</span> Protein-coding gene in the species Homo sapiens

Defensin, alpha 6 (DEFA6) also known as human alpha defensin 6 (HD6) is a human protein that is encoded by the DEFA6 gene. DEFA6 is expressed in the Paneth cells of the ileum.

<span class="mw-page-title-main">DEFA4</span> Protein-coding gene in the species Homo sapiens

Defensin, alpha 4 (DEFA4), also known as neutrophil defensin 4 or HNP4, is a human defensin peptide that is encoded by the DEFA4 gene. HNP4 is expressed in the granules of the neutrophil where it defends the host against bacteria and viruses.

Theta-defensins are a family of mammalian antimicrobial peptides. They are found in non-human 'Old World' primates, but not in human, gorilla, bonobo, and chimpanzee.

<span class="mw-page-title-main">Tachystatin</span>

Tachystatins are antimicrobial chitin-binding peptides from Japanese horseshoe crab. Amino acid residues Tyr(14) and Arg(17) in Tachystatin B are thought to be the essential residues for chitin binding. These small proteins contain a cysteine-stabilised triple-stranded beta-sheet with an inhibitor cystine knot motif and show features common to membrane-interactive peptides. Tachystatin A is thought to have an antimicrobial activity similar to defensins.

Virtual colony count (VCC) is a kinetic, 96-well microbiological assay originally developed to measure the activity of defensins. It has since been applied to other antimicrobial peptides including LL-37. It utilizes a method of enumerating bacteria called quantitative growth kinetics, which compares the time taken for a bacterial batch culture to reach a threshold optical density with that of a series of calibration curves. The name VCC has also been used to describe the application of quantitative growth kinetics to enumerate bacteria in cell culture infection models. Antimicrobial susceptibility testing (AST) can be done on 96-well plates by diluting the antimicrobial agent at varying concentrations in broth inoculated with bacteria and measuring the minimum inhibitory concentration that results in no growth. However, these methods cannot be used to study some membrane-active antimicrobial peptides, which are inhibited by the broth itself. The virtual colony count procedure takes advantage of this fact by first exposing bacterial cells to the active antimicrobial agent in a low-salt buffer for two hours, then simultaneously inhibiting antimicrobial activity and inducing exponential growth by adding broth. The growth kinetics of surviving cells can then be monitored using a temperature-controlled plate reader. The time taken for each growth curve to reach a threshold change in optical density is then converted into virtual survival values, which serve as a measure of antimicrobial activity.

Ribosomally synthesized and post-translationally modified peptides (RiPPs), also known as ribosomal natural products, are a diverse class of natural products of ribosomal origin. Consisting of more than 20 sub-classes, RiPPs are produced by a variety of organisms, including prokaryotes, eukaryotes, and archaea, and they possess a wide range of biological functions.

<span class="mw-page-title-main">Murepavadin</span> Chemical compound

Murepavadin also known as POL7080 is a Pseudomonas specific peptidomimetic antibiotic. It is a synthetic cyclic beta hairpin peptidomimetic based on the cationic antimicrobial peptide protegrin I (PG-1) and the first example of an outer membrane protein-targeting antibiotic class with a novel, nonlytic mechanism of action, highly active and selective against the protein transporter LptD of Pseudomonas aeruginosa. In preclinical studies the compound was highly active on a broad panel of clinical isolates including multi-drug resistant Pseudomonas bacteria with outstanding in vivo efficacy in sepsis, lung, and thigh infection models. Intravenous murepavadin is in development for the treatment of bacterial hospital-acquired pneumonia and bacterial ventilator-associated pneumonia due to Pseudomonas aeruginosa.

A proteolipid is a protein covalently linked to lipid molecules, which can be fatty acids, isoprenoids or sterols. The process of such a linkage is known as protein lipidation, and falls into the wider category of acylation and post-translational modification. Proteolipids are abundant in brain tissue, and are also present in many other animal and plant tissues. They include ghrelin, a peptide hormone associated with feeding. Many proteolipids are composed of proteins covalenently bound to fatty acid chains, often granting them an interface for interacting with biological membranes. They are not to be confused with lipoproteins, a kind of spherical assembly made up of many molecules of lipids and some apolipoproteins.

<span class="mw-page-title-main">Cinnamycin</span> Cinnamycin is a type B lantibiotic produced by Streptomyces cinnamoneus

Cinnamycin is a tetracyclic antibacterial peptide produced by Streptomyces cinnamoneus containing 19 amino acid residues including the unusual amino acids threo-3-methyl-lanthionine, meso-lanthionine, lysinoalanine, and 3-hydroxyaspartic acid.

References

  1. 1 2 3 Kokryakov VN, Harwig SS, Panyutich EA, Shevchenko AA, Aleshina GM, Shamova OV, Korneva HA, Lehrer RI (July 1993). "Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins". FEBS Letters. 327 (2): 231–6. doi: 10.1016/0014-5793(93)80175-T . PMID   8335113.
  2. ↑ Jang H, Ma B, Nussinov R (April 2007). "Conformational study of the protegrin-1 (PG-1) dimer interaction with lipid bilayers and its effect". BMC Structural Biology. 7: 21. doi: 10.1186/1472-6807-7-21 . PMC   1858697 . PMID   17407565.
  3. ↑ Kandasamy SK, Larson RG (2007). "Binding modes of protegrin-1, a beta-strand antimicrobial peptide, in lipid bilayers". Molecular Simulation. 9 (10): 799–807. doi:10.1080/08927020701313737. S2CID   98222970.
  4. ↑ Yasin B, Harwig SS, Lehrer RI, Wagar EA (March 1996). "Susceptibility of Chlamydia trachomatis to protegrins and defensins". Infection and Immunity. 64 (3): 709–13. doi:10.1128/IAI.64.3.709-713.1996. PMC   173826 . PMID   8641770.
  5. 1 2 3 4 5 Miyasaki KT, Iofel R, Lehrer RI (August 1997). "Sensitivity of periodontal pathogens to the bactericidal activity of synthetic protegrins, antibiotic peptides derived from porcine leukocytes". Journal of Dental Research. 76 (8): 1453–9. doi:10.1177/00220345970760080701. PMID   9240381. S2CID   46414982.
  6. ↑ Zhao C, Ganz T, Lehrer RI (July 1995). "The structure of porcine protegrin genes". FEBS Letters. 368 (2): 197–202. doi:10.1016/0014-5793(95)00633-K. PMID   7628604. S2CID   38194027.
  7. ↑ Zhao C, Liu L, Lehrer RI (June 1994). "Identification of a new member of the protegrin family by cDNA cloning". FEBS Letters. 346 (2–3): 285–8. doi: 10.1016/0014-5793(94)00493-5 . PMID   8013647.
  8. ↑ Panchal RG, Smart ML, Bowser DN, Williams DA, Petrou S (June 2002). "Pore-forming proteins and their application in biotechnology". Current Pharmaceutical Biotechnology. 3 (2): 99–115. doi:10.2174/1389201023378418. PMID   12022262.
  9. 1 2 Sokolov Y, Mirzabekov T, Martin DW, Lehrer RI, Kagan BL (August 1999). "Membrane channel formation by antimicrobial protegrins". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1420 (1–2): 23–9. doi:10.1016/S0005-2736(99)00086-3. PMID   10446287.
  10. ↑ Drin G, Temsamani J (February 2002). "Translocation of protegrin I through phospholipid membranes: role of peptide folding". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1559 (2): 160–70. doi:10.1016/S0005-2736(01)00447-3. PMID   11853682.
  11. ↑ Fahrner RL, Dieckmann T, Harwig SS, Lehrer RI, Eisenberg D, Feigon J (July 1996). "Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide from porcine leukocytes". Chemistry & Biology. 3 (7): 543–50. doi: 10.1016/S1074-5521(96)90145-3 . PMID   8807886.
  12. ↑ Lai JR, Huck BR, Weisblum B, Gellman SH (October 2002). "Design of non-cysteine-containing antimicrobial beta-hairpins: structure-activity relationship studies with linear protegrin-1 analogues" (PDF). Biochemistry. 41 (42): 12835–42. doi:10.1021/bi026127d. PMID   12379126. Archived from the original (PDF) on 2008-12-05. Retrieved 2009-04-27.
  13. 1 2 Gidalevitz D, Ishitsuka Y, Muresan AS, Konovalov O, Waring AJ, Lehrer RI, Lee KY (May 2003). "Interaction of antimicrobial peptide protegrin with biomembranes". Proceedings of the National Academy of Sciences of the United States of America. 100 (11): 6302–7. Bibcode:2003PNAS..100.6302G. doi: 10.1073/pnas.0934731100 . PMC   164441 . PMID   12738879.
  14. ↑ Cho Y, Turner JS, Dinh NN, Lehrer RI (June 1998). "Activity of protegrins against yeast-phase Candida albicans". Infection and Immunity. 66 (6): 2486–93. doi:10.1128/IAI.66.6.2486-2493.1998. PMC   108228 . PMID   9596706.
  15. ↑ Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME (August 1989). "Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity". The Journal of Clinical Investigation. 84 (2): 553–61. doi:10.1172/JCI114198. PMC   548915 . PMID   2668334.
  16. ↑ Qu XD, Harwig SS, Oren AM, Shafer WM, Lehrer RI (April 1996). "Susceptibility of Neisseria gonorrhoeae to protegrins". Infection and Immunity. 64 (4): 1240–5. doi:10.1128/IAI.64.4.1240-1245.1996. PMC   173910 . PMID   8606085. Archived from the original on 2011-07-26. Retrieved 2009-04-27.
  17. ↑ Tamamura H, Murakami T, Horiuchi S, Sugihara K, Otaka A, Takada W, Ibuka T, Waki M, Yamamoto N, Fujii N (May 1995). "Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity". Chemical & Pharmaceutical Bulletin. 43 (5): 853–8. doi: 10.1248/cpb.43.853 . PMID   7553971.
  18. ↑ Gabay JE (April 1994). "Ubiquitous natural antibiotics". Science. 264 (5157): 373–4. Bibcode:1994Sci...264..373G. doi:10.1126/science.8153623. PMID   8153623.
  19. ↑ Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, Van der Meijden B, Bernardini F, Lederer A, Dias RL, Misson PE, Henze H, Zumbrunn J, Gombert FO, Obrecht D, Hunziker P, Schauer S, Ziegler U, Käch A, Eberl L, Riedel K, DeMarco SJ, Robinson JA (February 2010). "Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa" (PDF). Science. 327 (5968): 1010–3. Bibcode:2010Sci...327.1010S. doi:10.1126/science.1182749. PMID   20167788. S2CID   430525.
  20. ↑ Zerbe K, Moehle K, Robinson JA (June 2017). "Protein Epitope Mimetics: From New Antibiotics to Supramolecular Synthetic Vaccines". Accounts of Chemical Research. 50 (6): 1323–1331. doi:10.1021/acs.accounts.7b00129. PMID   28570824.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.